Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dasabuvir - AbbVie

Next Previous
Drug Profile

Dasabuvir - AbbVie

Alternative Names: ABT-333; Exviera; Viekira Pak (dasabuvir combination therapy); VIEKIRA XR

Latest Information Update: 09 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Antivirals; Naphthalenes; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 25 Sep 2024 Regulatory submission withdrawn for Hepatitis C (Combination therapy) in European Union (PO)
  • 13 May 2021 AbbVie completes the phase III TOPAZ-I trial in Hepatitis C (Combination therapy) in Algeria, Australia, Austria, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russia, South Arabia, Spain, Sweden, Switzerland, Turkey and United Kingdom (PO) (NCT02219490)
  • 13 May 2021 AbbVie completes the phase III TOPAZ II trial for Hepatitis C (Combination therapy, In adults, In the elderly) in USA (NCT02167945)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top